(0.23%) 5 143.50 points
(0.23%) 38 530 points
(0.32%) 17 904 points
(-0.89%) $83.10
(1.82%) $1.958
(-0.19%) $2 342.70
(0.00%) $27.54
(0.43%) $926.10
(-0.17%) $0.933
(-0.10%) $11.01
(-0.25%) $0.798
(0.74%) $92.55
3 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 7.20%
Live Chart Being Loaded With Signals
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults...
Stats | |
---|---|
今日成交量 | 41 555.00 |
平均成交量 | 54 452.00 |
市值 | 131.23M |
EPS | $0 ( 2024-03-07 ) |
下一个收益日期 | ( $-0.220 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.790 |
ATR14 | $0.0100 (1.47%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-08 | Tasse Daniel | Buy | 17 094 | Ordinary Shares |
2024-02-06 | Ndu Adora | Buy | 1 825 | Ordinary Shares |
2023-11-22 | Mohideen Pharis | Sell | 2 245 | Ordinary Shares |
2023-11-20 | Boucinha Virginie | Buy | 113 000 | Employee Stock Option (right to buy) |
2023-11-20 | Boucinha Virginie | Buy | 19 000 | Ordinary Shares |
INSIDER POWER |
---|
99.85 |
Last 57 transactions |
Buy: 29 162 445 | Sell: 1 080 406 |
DBV Technologies S.A. 财务报表
Annual | 2023 |
营收: | $15.73M |
毛利润: | $20.23M (128.59 %) |
EPS: | $-0.380 |
FY | 2023 |
营收: | $15.73M |
毛利润: | $20.23M (128.59 %) |
EPS: | $-0.380 |
FY | 2022 |
营收: | $4.80M |
毛利润: | $-16.53M (-344.46 %) |
EPS: | $-0.620 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-0.890 |
Financial Reports:
No articles found.
DBV Technologies S.A.
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。